McKesson Q3 FY26: where the revenue came from and where it went
The whole income statement of McKesson for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 4, 2026
Revenue$106.16B
+11% year over year
Gross profit$3.69B
3% margin
Operating profit$1.62B
2% margin
Net profit$1.19B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 106.16 | 100% | +11% |
| North american | 88.32 | 83% | |
| Oncology & multispecialty | 13.01 | 12% | |
| Medical-Surgical | 2.99 | 3% | |
| Prescription technology | 1.50 | 2% | |
| Other revenue | 0.34 | 0% | |
| Cost of revenue | −102.47 | 97% | |
| Gross profit | 3.69 | 3% margin | +0pp |
| SG&A | −2.03 | 2% | +0pp |
| Other | −0.04 | 0% | +0pp |
| Operating profit | 1.62 | 2% margin | |
| Interest & other costs | −0.05 | ||
| Tax | −0.38 | ||
| Net profit | 1.19 | 1% margin | +0pp |
124 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest